Psychological Distress in Patients With Bladder Cancer
Clinical factors associated with an increased risk of psychological distress included younger age, female sex, advanced pathological/tumor stage, and preoperative setting.
Related Articles
Tripokin: A multi‐specific immunocytokine for cancer immunotherapy
What’s new? The anticancer cytokines interleukin-2 (IL-2) and tumor-necrosis factor (TNF) exhibit remarkable efficacy against tumors. Their therapeutic potential, however, is limited by significant t…
Long-Term Data Testing Treatment in Patients With Thyroid Eye Disease
Prem Subramanian, MD, PhD, discusses long-term data testing teprotumumab in patients with thyroid eye disease (TED).
Venetoclax Plus 10-Day Decitabine Produces Responses in High-Risk MDS, AML
Venetoclax plus 10-day decitabine was safe and produced responses in AML and high-risk MDS.
Accelerated Approval Sought for RP1 Plus Nivolumab in Advanced Melanoma
A biologics license application was submitted to the FDA seeking the approval of RP1 plus nivolumab for patients with PD-1 inhibitor–exposed melanoma.
Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer
Nature – The phase 3 SONIA trial challenges the benefits of using cyclin-dependent kinase 4 and 6 inhibitors as a first-line compared with second-line treatment.
EMERALD subgroup analysis: Elacestrant in endocrine-sensitive disease
Along with the Oncology Brothers, Paolo Tarantino, MD, discusses the post -hoc subgroup analysis from the EMERALD study (SABCS 2023), which examined outcomes in patients…
Adding an HPK1 Inhibitor to Immune Checkpoint Inhibition May Be Effective in Solid Tumors
Anita Scheuber, MD, PhD, details how HPK1 inhibition may enhance the antitumor activity of ICIs in solid tumors, diving into the agent NDI-101150 in particular.
Bispecific Antibodies and CAR T-Cell Therapies Continue to Reshape Myeloma Treatment Landscape
Syed Abbas Ali, MBBS, discusses how CAR T-cell therapies and bispecific antibodies have altered treatment in relapsed/refractory multiple myeloma.
Report on Artificial Intelligence and Health Insurance – Consumer Health Reps at NAIC
This report was compiled by NORC at the University of Chicago on behalf of the Consumer Representatives to the NAIC. The report examines the current…
Comparative Efficacy and Future Directions in SCLC Treatment
Joshua K. Sabari, MD, evaluates the objective clinical outcomes of emerging targeted therapies for ES-SCLC, comparing them with second-line topotecan and CAV regimens, while discussing…